ArticleAnnals of medicine2025
Effects of preexisting and new-onset diabetes mellitus on clinical outcomes of patients with heart failure.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- snRNA-seq identifies Fmo2npj metabolic health and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus (DM) is a common comorbidity in heart failure (HF), but the impact of new-onset DM on HF outcomes remains unclear. This study evaluated the effects of DM status on hospitalization for HF (HHF), major adverse cardiac events (MACEs), and mortality in HF patients.
methodsWe conducted a retrospective cohort study of patients newly diagnosed HF at Changhua Christian Hospital, Taiwan, from 2011 to 2021. Patients were grouped as non-DM (
resultsCompared to the non-DM group, the preexisting DM was associated with higher risks of HHF [hazard ratio (HR), 1.13; 95% confidence interval (CI), 1.02-1.25], MACEs (HR, 1.22; 95% CI, 1.00-1.49), all-cause mortality (HR, 1.17; 95% CI, 1.01-1.36), and cardiovascular death (HR, 1.54; 95% CI, 1.15-2.06). The new-onset DM group showed a significantly higher risk of HHF (HR, 1.24; 95% CI, 1.01-1.51) and MACEs (HR, 1.22; 95% CI, 1.00-1.49), with nonsignificant trends toward increased all-cause mortality (HR, 1.08; 95% CI, 0.79-1.48) and cardiovascular death (HR, 1.36; 95% CI, 0.74-2.48).
conclusionIn HF patients, preexisting DM is associated with worse outcomes across multiple endpoints. New-onset DM also elevates risks of HHF and MACE, though its effect on mortality is less clear. Although our study, utilizing electronic medical record data, revealed a different pattern compared to the Danish registry, the findings emphasize the need for individualized management strategies based on DM status in HF care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.